Pennington A M, Bronk J R
Department of Biology, University of York, UK.
Cancer Chemother Pharmacol. 1995;36(2):136-42. doi: 10.1007/BF00689198.
The intestinal absorption of 6-mercaptopurine and its nucleoside 6-mercaptopurine riboside has been studied in the rat with the in situ dual luminal and vascular perfusion. 6-Mercaptopurine is an inactive prodrug that requires intestinal absorption, cellular uptake and intracellular anabolism for cytotoxic activity. Vascular and mucosal samples were analysed by high-performance liquid chromatography (HPLC) to assess the rate of vascular appearance and amounts of thiopurine and its nucleoside in the mucosa. With 5 mmol luminal 6-mercaptopurine/l, the drug is transported across the intestine unchanged at a rate of 0.053 +/- 0.006 mumol min-1 (g dry wt.)-1. At concentrations below 20 mmol/l, 6-mercaptopurine riboside is not transported across the intestine intact but is split by phosphorolysis in the intestinal mucosa. The rate of vascular appearance of 6-mercaptopurine [0.043 +/- 0.005 mumol min-1 (g dry wt.)-1] from 5 mmol luminal 6-mercaptopurine riboside/l did not differ significantly from that seen with 5 mmol luminal 6-mercaptopurine/l. When the lumen was perfused with 6-mercaptopurine riboside the riboside appeared in the tissue together with a higher mucosal concentration of 6-mercaptopurine than in perfusions with 6-mercaptopurine. Some metabolism of 6-mercaptopurine to 6-thioguanine was also observed; however, no 6-thioguanine appeared in the vascular effluent. Increasing the luminal phosphate concentration from 2 to 10 mmol/l increased mucosal phosphorolysis of 6-mercaptopurine riboside and more than tripled the rate of vascular appearance of 6-mercaptopurine; conversion of 6-mercaptopurine to 6-thioguanine was significantly inhibited. These results suggest that with a modest increase in luminal phosphate concentration, 6-mercaptopurine riboside can be a more effective substrate than the free drug for the oral delivery of 6-mercaptopurine.
利用原位双腔和血管灌注技术,在大鼠体内研究了6-巯基嘌呤及其核苷6-巯基嘌呤核糖苷的肠道吸收情况。6-巯基嘌呤是一种无活性的前体药物,需要经过肠道吸收、细胞摄取和细胞内合成代谢才能发挥细胞毒性作用。通过高效液相色谱法(HPLC)分析血管和黏膜样本,以评估硫嘌呤及其核苷在血管中的出现速率和在黏膜中的含量。当管腔内6-巯基嘌呤浓度为5 mmol/L时,该药物以0.053±0.006 μmol·min⁻¹·(g干重)⁻¹的速率完整地穿过肠道。在浓度低于20 mmol/L时,6-巯基嘌呤核糖苷不会完整地穿过肠道,而是在肠道黏膜中被磷酸解作用分解。5 mmol/L管腔内6-巯基嘌呤核糖苷产生的6-巯基嘌呤在血管中的出现速率[0.043±0.005 μmol·min⁻¹·(g干重)⁻¹]与5 mmol/L管腔内6-巯基嘌呤的情况相比,差异不显著。当向管腔内灌注6-巯基嘌呤核糖苷时,核糖苷出现在组织中,同时黏膜中6-巯基嘌呤的浓度高于灌注6-巯基嘌呤时的浓度。还观察到6-巯基嘌呤有一些代谢为6-硫鸟嘌呤的情况;然而,血管流出液中未出现6-硫鸟嘌呤。将管腔内磷酸盐浓度从2 mmol/L提高到10 mmol/L,可增加6-巯基嘌呤核糖苷的黏膜磷酸解作用,并使6-巯基嘌呤在血管中的出现速率增加两倍多;6-巯基嘌呤向6-硫鸟嘌呤的转化受到显著抑制。这些结果表明,随着管腔内磷酸盐浓度适度增加,6-巯基嘌呤核糖苷作为6-巯基嘌呤口服给药的底物可能比游离药物更有效。